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Aortic Regurgitation: Time to Reassess Timing of Valve
Replacement?*
Robert O. Bonow, MD
Chicago, Illinoisf
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fMajor advances in cardiac surgery and interventional
cardiology over the past several decades have led to a
gradual but substantial reduction in the threshold for
cardiac valve replacement and repair. Whereas 30 to
40 years ago, surgery was indicated only when patients
manifested severe symptoms, the field has progressed
to the point at which current guidelines recommend
intervening at the first onset of even mild symptoms
and even in selected asymptomatic patients (1,2).
See page 223
Early referral for valve repair or replacement is
justified when it is substantiated by the available
natural history data and extensive clinical experi-
ence, and this is the case for many disorders of the
aortic and mitral valves. However, the management
of patients with aortic regurgitation (AR), in par-
ticular, remains problematic.
Percutaneous mitral balloon valvotomy offers a
safe and effective treatment of mitral stenosis with
excellent long-term results, and patients who are
suitable candidates are recommended to undergo
this intervention at an earlier stage of symptoms or
pulmonary hypertension than are patients with
severe valve deformities that require surgical valve
replacement. Referral for mitral valve repair in
asymptomatic patients with severe degenerative
forms of mitral regurgitation (MR), the leading
cause of MR in developed countries, is supported by
natural history studies indicating a rapid progres-
sion toward symptoms, left ventricular (LV) dys-
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ion, and by studies indicating worse post-operative
urvival among patients with pre-operative symp-
oms compared to asymptomatic patients (3). Sim-
larly, among patients with aortic stenosis (AS), the
igh likelihood that a patient with severe AS will
equire aortic valve replacement (AVR) within 5
ears or less, coupled with concerns of sudden
eath, the difficulty in eliciting symptoms in seden-
ary patients, and the low operative risk in experi-
nced centers, have led to consideration for early
VR in many patients (1–5). In contrast to this
rowing consensus regarding management of patients
ith mitral stenosis, MR, and AS, the timing of AVR
n patients with AR continues to stand out as a subject
f uncertainty and considerable controversy.
Optimal timing of AVR in patients with AR is
roblematic as they may remain asymptomatic with
ormal LV systolic function for many years despite
he substantial LV volume load, yet by the time
ymptoms develop, a large number may have al-
eady developed myocardial dysfunction that may
lace them at high risk for post-operative heart
ailure and death. Unlike the trend for early surgery
n asymptomatic patients with severe MR, the
ajority of whom are candidates for mitral valve
epair, a higher threshold for surgery is set for
atients with AR as they almost always face valve
eplacement. The time course toward development
f symptoms and/or LV systolic dysfunction is
radual and protracted in younger patients with AR
1,6–8), although this appears to be a more rapid
rocess in patients older than 50 years of age (9).
onetheless, the average age of patients with severe
R is significantly less than that of patients under-
oing surgery for severe AS, for whom the decision
o replace the valve with a bioprosthesis is straight-
orward. In contrast, determining the optimum
ime for valve replacement in young asymptomatic
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232patients with severe AR, and then selecting a
mechanical prosthesis versus a bioprosthesis, pres-
ent difficult, if not agonizing, decisions for the
clinician.
Guideline recommendations for AVR in asymp-
tomatic patients with AR have historically focused
on LV ejection fraction and LV end-systolic di-
mension as measures of LV pump performance, and
LV end-diastolic dimension as a measure of the
severity of the volume overload (1,2). In addition to
the inherent variability of these measurements,
ejection fraction notoriously may fluctuate depend-
ing on blood pressure and other loading conditions,
and LV short-axis diameters fail to adequately
reflect the great individual variation in the
3-dimensional geometries of volume-loaded left
ventricles. However, these simple measurements
were those available to the investigators more than
a decade ago who performed the long-term natural
history and outcome studies that are the substrate
for the current guidelines. In essence, the guidelines
are based on 30-year-old technology. Although a
more rigorous assessment of LV regional and global
performance should be possible with our current
imaging armamentarium, new evidence has yet to
materialize to guide management decisions. Only
recently have standardized criteria for LV volume
measurements by echocardiography been estab-
lished (9,10), and these have not been subjected to
extensive long-term studies of sufficiently large
numbers of patients. Newer methods to assess
systolic and diastolic myocardial function with car-
diac magnetic resonance or echocardiographic
methods such as tissue Doppler imaging or speckle
tracking are now available, but these too require
careful prospective investigation to determine their
potential role in clinical decision making.
In the current issue of iJACC, Olsen et al. (11)
have moved the field several steps forward by
examining the potential of speckle-tracking echo-
cardiography to predict clinical and functional
changes over the course of time in asymptomatic
patients with AR and normal LV systolic function
and, in another group of patients undergoing AVR,
to predict changes in LV function after surgery. In
both groups of patients, reduced systolic strain,
systolic strain rate, and diastolic strain were associ-
ated with worse outcome: more rapid progression of
disease in the asymptomatic patients during conser-
vative follow-up and worse functional outcome after
AVR in the surgery group. These seminal findings
and their intriguing implications regarding future
clinical implementation need to be balanced againstseveral limitations, some of which are noted by the
authors themselves.
First and foremost, Olsen et al. (11) studied only
a small number of patients—35 in the serial
follow-up group and 29 in the surgical group—
which not only limited the ability to perform
multivariate or subset analyses (as noted), but also
required the use of composite end points, which
comprised both clinical and LV function data.
Changes in function represent only intermediate
outcomes, and whether these translate into hard
outcomes such as death, hospitalization, and quality
of life is uncertain. The heterogeneous use of
medications that might influence LV performance
is an additional confounder. The number of pa-
tients in each of the 2 groups is too small, the
follow-up periods too short, and the use of drugs
too nonuniform to draw meaningful conclusions
other than that this is a promising technique worthy
of further investigation.
Second, the subgroup of surgical patients with
the suboptimal outcome after AVR included many
with such severe pre-operative LV dysfunction
and/or LV dilation that it is not surprising that they
also had other measures of impaired LV function
that “predicted” the worse outcome. Whether
speckle tracking adds incremental information to
standard measures of LV volume and function in
this situation is unclear; one would need to study a
larger number of patients undergoing AVR with
more normal ejection fraction and less severe dila-
tion to determine if this technology is helpful in
predicting post-operative outcome and, thus, in
selecting patients for possible earlier surgery.
As the current data suggest a possible role of
strain analysis in asymptomatic patients with pre-
served systolic function, it is noteworthy that a large
number of patients in the conservative follow-up
group reached an end point in a very short time:
25% of patients reached an end point during a mean
follow-up period of only 19 months. This attrition
rate is much more rapid than that reported in most
natural history studies, in which the average is 4.3%
per year (1,6–8), but is a similar pattern to that
reported in the first paper published in the inaugu-
ral issue of iJACC by Detaint et al. (9). The
common thread may be the mean ages of the
patients: 60 years in the Detaint report and 57 years
in the current study, compared to 36, 41, and 46
years in the reports of Bonow et al. (6), Tornos et al.
(7), and Borer et al. (8), respectively. The mean age
of patients in the natural history series cited in the
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233Association guidelines is 39 years. The implications
are that older patients with asymptomatic AR have
a much higher rate of development of symptoms
and/or LV dysfunction than do younger patients,
which may be related to effects of aging on vascular
and myocardial stiffness that poorly tolerate a sig-
nificant volume load. This observation suggests that
the search for additional measures of LV perfor-
mance beyond the standards of ejection fraction and
volume is on the right track in older patients with4. Malaisrie SC, McCarthy PM, McGee
EC, et al. Contemporary perioperative
mal left ventricular
culation 1998;97:52strain may provide the key in such patients. Larger
series with longer follow-up periods and rigorous
control of medications are needed to determine
whether this is the case and whether measures of
myocardial strain have a place in the mainstream
evaluation of patients with AR.
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